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Abstract
Proteins that perform active transport must alternate the access of a binding site, first to one side of a
membrane and then to the other, resulting in the transport of bound substrates across the membrane. To
better understand this process, we sought to identify mutants of the small multidrug resistance transporter
EmrE with reduced rates of alternating access. We performed extensive scanning mutagenesis by changing
every amino acid residue to Val, Ala, or Gly, and then screening the drug resistance phenotypes of the
resulting mutants. We identified EmrE mutants that had impaired transport activity but retained the ability to
bind substrate and further tested their alternating access rates using NMR. Ultimately, we were able to identify
a single mutation, S64V, which significantly reduced the rate of alternating access but did not impair substrate
binding. Six other transport-impaired mutants did not have reduced alternating access rates, highlighting the
importance of other aspects of the transport cycle to achieve drug resistance activity in vivo. To better
understand the transport cycle of EmrE, efforts are now underway to determine a high-resolution structure
using the S64V mutant identified here.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).

Introduction
The small multidrug resistance transporter EmrE
harnesses the energy of the proton motive force to
confer resistance to a wide array of toxic cations [1].
EmrE functions as an antiparallel homodimer, with a
shared binding site for both protons and drug
substrates [2–5]. The dynamic process of switching
conformations so that this binding site alternates
between inward facing and outward facing is the
key step in moving substrates across the membrane
(Fig. 1). When this alternating access process is
prevented by specific cross-linking, EmrE is rendered
nonfunctional, providing experimental confirmation
that alternating access is required for transport [6].
Multiple laboratories have investigated the impact of
individual mutations on EmrE function. Several
common themes emerged from these studies, such

as the importance of Glu14 as a shared binding site
both for drugs and protons, the role of transmembrane
helices 1, 2, and 3 (TMs 1–3) as the core substrate
binding domain, and the role of TM4 as a dimerization
domain. These studies identified specific residues
critical for drug binding, drug specificity, proton–drug
coupling, and dimerization [2,7–17]. However, no
individual sites have previously been identified as
critical for alternating access.
EmrE is the most studied member of the small
multidrug resistance family and is the only small
multidrug resistance transporter for which even modest resolution structures are available [3,4,18]. These
structures provided crucial insight into the surprising
asymmetric, antiparallel topology of EmrE, but the lack
of side chain information hinders a deeper understanding of the transport mechanism. More recently,
two models of the EmrE structure have been published
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[19,20] based on molecular dynamics simulations of
EmrE embedded in lipid bilayers. While these models
provide useful information on the transport cycle [19]
and dimerization [20] of EmrE, they are ultimately
based on the earlier low-resolution experimental
structures. There are several potential reasons why a
high-resolution structure has proven elusive. First,
EmrE is quite small, with short loops connecting four
transmembrane helices in only 110 total amino acids.
The lack of soluble domains hampers threedimensional crystallization, and strategies that have
proven useful for solving the structure of other integral
membrane proteins have been unsuccessful for EmrE.
Second, EmrE is inherently dynamic. In fact, there is no
known condition under which wild-type EmrE is not
dynamic; alternating access occurs even when neither
proton nor drug is bound [21–24]. This natural plasticity
is proposed to be an important property enabling its
very broad multidrug binding capability [23] but is
problematic for the determination of high-resolution
structures. Therefore, we have a second motivation in
identifying a mutant that suppresses the inherently
dynamic nature of EmrE in order to determine a higher
resolution structure and better understand how this
small protein interacts with such a broad class of
substrates.
Here, we identify a critical residue in EmrE, S64V,
which alters the rate of alternating access but does not
significantly change the affinity for substrate binding.

Results
Identification of functionally important residues
in EmrE
To efficiently screen for potential dynamics mutants,
we took advantage of the fact that alternating access is
required for transport. Thus, we sought to identify
EmrE point mutations that inhibited transport, as
measured by inability to confer resistance to toxic
compounds when expressed in Escherichia coli. First,
wild-type EmrE was mutated at every residue
(except the N-terminal Met) to the amino acids Ala,
Gly, or Val as described in Materials and Methods. In a
few positions, Leu was introduced if the native amino
acid was already Ala, Gly, or Val. Previous scanning
mutagenesis of EmrE used Cys or Trp substitutions to
probe residue accessibility, identify the dimer inter-
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face, and insert spin labels for electron paramagnetic
resonance studies [8,9,11,13,16,25,26]. However,
Ala, Gly, and Val are more common in transmembrane
helical regions than Cys or Trp [27,28]. Substitutions
with these three amino acids are well tolerated
throughout a membrane protein and have been used
previously to isolate conformational specific mutants
of the tetracycline carrier TetA(B) [29]. After two
rounds of mutagenesis, all but five mutants were
made (F44A, W63 V, F79G, D84A, I88G). The EmrE
mutants were then tested for their ability to confer
resistance to three canonical EmrE substrates: methyl
viologen, acriflavine, and ethidium bromide (Figs. S1–
S3, Supplementary Data Table 1). Two concentrations
of each substrate (see Materials and Methods) were
chosen for testing. These concentrations were selected
so that E. coli strain JM109 containing the plasmid
pKK223-3 was unable to grow even at the lower
concentration and leaky expression of wild-type emrE
from the same plasmid was still able to confer
resistance and permit growth of JM109 at the higher
concentration. Growth was scored as robust at both
concentrations of a given substrate (++), growth at
both substrate concentrations but notably reduced
relative to WT at the higher concentration (+), growth
only at the lower substrate concentration (+/−), or no
growth at either substrate concentration (−) for each of
the three different substrates.
Mapping the transport activity of the EmrE
mutants onto the recent all-atom model[19] of
EmrE (Fig. 2a) highlights the similarity between
the functionally important residues identified experimentally and regions of high-sequence conservation as identified using ConSurf (Fig. 2b). The
screen identified residues in TM1–3 lining the
substrate binding pocket known to be important
for drug and proton binding (e.g., Glu14, Leu47, and
Trp63) [2,11,12], as well as residues in the TM4
dimerization interface (Gly90, Ile94, and Gly97)
[10,13,20]. As expected, many locations were
sensitive to the identity of the substituted amino
acid (Fig. 3a). For example, mutation of Ala10—
located just one helical turn away from the Glu14
binding site—to the bulkier valine abolished resistance to all three substrates, while mutation to
glycine did not impair the resistance phenotype. In
addition, by testing growth on three different EmrE
substrates, our scan highlights residues where
mutation has a potential effect on drug selectivity

Fig. 1. Alternating-access of EmrE. EmrE binds
both protons and polyaromatic cation substrates at a
shared binding site defined by the two E14 residues
from the two protomers of the functional homodimer.
Alternating accessibility of this binding site to either side
of the membrane occurs when the two protomers in the
antiparallel homodimer swap conformational states (illustrated by the different shapes drawn for each protomer). EmrE couples
proton import to export of toxic substrates, conferring resistance to these compounds to E. coli.
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(Fig. 3b). Many residues thought to interact with
substrates, such as Leu7 and Phe44 [8], conferred
varying levels of resistance to different drugs. This
supports the hypothesis that substrates with widely
variant structures do not necessarily interact with
identical amino acid residues and could affect the
EmrE structural intermediates differently [30]. Interestingly, a number of residues from the TM2–3
loop and from TM4 had an effect on substrate
selectivity, even though these regions are not part
of the previously identified substrate binding site
[2–5].
Identification of potential EmrE dynamics mutants
Impaired drug-efflux activity could result from disruption of any one of the steps in the transport cycle.
Alternating access between outward-open and
inward-open states is essential for EmrE to confer
drug resistance [6] but is not necessary for drug
binding. Therefore, in order to identify mutants of EmrE
more likely to have impaired alternating access rates,
we first identified mutants with impaired resistance
phenotypes we excluded mutations to residues known
to be involved in drug binding and focused on sites that

Fig. 2. Functionally critical residues in EmrE identified from screening are evolutionarily conserved.
(a) Summary of plate assay results
from Supplementary Data Table 1
mapped on to the complete structural
model of EmrE [19]. Gray, no effect
(++) of mutation to V, A, or G at that
position on resistance to any of
the tested compounds. Blue, modest
effect (+) of mutation on resistance
profile. Magenta, significant effect
(+/−) of mutation on resistance profile.
Red, severe defect (−) in growth or
resistance to all tested compounds
upon mutation of that position to any
other amino acid. (b) Evolutionary
conservation profile calculated using
ConSurf.

were not thought to be involved in direct interactions
with substrates. The mutants chosen were M21G,
A59L, S64V, G67A, G90V, G97V, I101G, N102A, and
N102V. We then tested the 3H-TPP +-binding affinity
of the selected mutants (Table 1). G67A and G97V
were excluded at this stage because expression was
very low, and they did not give good saturation binding
curves, suggesting that they would not be able to be
purified for structure determination. Four mutants
showed affinities of 3 H-TPP similar to wild type
EmrE (S64V, I101G, N102A, N102V), two mutants
had affinities 2- to 3-fold lower (M21G, G90V) and
one was 10-fold lower (A59L). The location of all
seven mutations is shown on the recently published
refined atomic model of the complete structure of
EmrE (Fig. 4a). M21G and A59L are located near the
ends of the first and second TM helices, respectively. S64V is close to the 65 GVG 67 TM3 kink region,
which is important for inward-open/outward-open
interconversion and multidrug recognition according
to cryo-EM and NMR studies [4,5,30,32,33]. G90V
is located in the established G90/G97 TM4 dimerization motif [10,13]. Finally, I101G, N102A, and
N102V are located in TM4 but have not been directly
implicated in dimerization.
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Fig. 3. Locations critical for function depend on identity of substituted
amino acid and identity of drug. (a)
Locations where the identity of the
substituted amino acid affects the
ethidium bromide resistance phenotype highlighted in red. (b) Locations
where different drug substrates led to
different growth phenotypes for one
of the substituted amino acids (blue)
or multiple amino acids (red).

90˚

Mutants with altered dynamics inhibit
EmrE-mediated drug efflux
To confirm the impaired transport phenotype, the
M21G, A59L, S64V, I101G, and N102A mutations
were further characterized using an ethidium efflux
assay in E. coli (Fig. 4b). This assay provided a
kinetic assessment of EmrE activity, compared to
the plate assay that simply reflected whether drug
efflux was sufficient to enable survival over 24 h. The
results confirmed that efflux of ethidium from E. coli
was indeed slower for each of the EmrE mutants
than for wild-type EmrE, and the slower efflux is not a
result of decreased EmrE expression (Fig. 4c). This
is consistent with the hypothesis that the impaired

Table 1. 3H-TPP + binding to EmrE mutants in DDM a
EmrE mutant
Wild type
M21G
A59L
S64V
G90V
I101G
N102A
N102V

Kd (nM)
0.8 ± 0.1
4.0 ± 0.7
23.4 ± 2.4
1.0 ± 0.6
5.3 ± 0.6
2.6 ± 1.3
2.3 ± 0.4
1.2 ± 0.2

a
Assays performed on ice, at pH 8. Binding affinity of TPP+ is in
nM range due to higher pH and lower temperature [5,31].

drug resistance activity of these EmrE mutants is
due to a reduced rate of alternating access.
The effect of the mutations upon EmrE dynamics
was then assessed using NMR spectroscopy, a
technique that is uniquely suited to provide information simultaneously about both protein structure and
dynamics. We acquired 1H– 15N TROSY HSQC
spectra of each mutant in q = 0.33 DMPC/DHPC
bicelles bound to tetraphenylphosphonium (TPP +)
and compared them to TPP +-bound WT EmrE under
the same conditions (Figs. 5 and S4). In the WT
spectrum, two peaks are visible for each residue,
reflecting the distinct chemical environments for
each protomer in the asymmetric dimer. Peak
doubling is still visible in the spectra for at least
some residues in six mutants, indicating that the
asymmetric EmrE dimer remains intact. The only
exception is G90V-EmrE, which has fewer peaks
and a poorly resolved spectrum, suggesting a loss of
its unique tertiary structure of the asymmetric dimer.
This is consistent with previous demonstrations that
the dimer is destabilized when G90 or G97 is
mutated [10,13].
The 1H– 15N TROSY spectra also provide substantial insight into protein dynamics. While each protomer
in the asymmetric dimer of EmrE is in a unique
chemical environment, the protomers swap conformations during alternating access [5]. The presence of
pairs of relatively sharp peaks for each amino acid in
the WT EmrE spectrum indicates that this alternating
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access rate is slow on the NMR timescale (kex b Δω,
where Δω is the chemical shift difference between the
two exchanging states) when TPP + is bound. If this
process were fast on the NMR timescale (kex N Δω),
then the spectrum would reflect an average of the two
chemical environments and only a single peak per
amino acid would be visible. Dynamics on intermediate
timescales result in significant broadening of the
peaks in the NMR spectrum. Despite our expectations
that impaired transport would arise from reduced
dynamics, five mutants displayed enhanced dynamics. The 1H– 15N TROSY spectra of I101G, A59L,
N102A, and N102V (Figs. 5 and S4) displayed
progressively increased line broadening, and each
pair of peaks shifted toward each other, eventually

500

Fig. 4. In-cell transport data confirm impaired transport phenotype.
(a) Position of putative dynamics
mutants on the structure, with wildtype residue identities indicated. (b)
Efflux of ethidium from BL21 (DE3)
E. coli cells transformed with either
empty vector or the indicated EmrE
mutant results in a decrease in
fluorescence. (c) Western blot of
selected EmrE mutants demonstrates that expression levels are
similar to WT-EmrE.

coalescing into a broad single peak for many residues.
It is important to note that the effect of dynamics on
peak widths and intensities is not limited to alternating
access conformational exchange. The enhanced line
broadening may also reflect greater structural heterogeneity or increased motion within the “ground-state”
structure. This is a more likely explanation for M21G,
which has significant loss of peak intensity while still
having well-resolved peak doubling.
Importance of the TM3 kink for alternating
access and drug transport by EmrE
In contrast to all other mutants, S64V-EmrE
displayed pairs of sharp, well-resolved peaks

2782

Alternating-Access Dynamics Mutant of EmrE

105

WT

A59L

110

115

120

125

130

105

I101G

S64V

110

115

120

125

130
10.5 10.0

9.5

9.0

8.5

8.0

7.5

7.0

10.5 10.0

9.5

9.0

8.5

8.0

7.5

7.0

Fig. 5. TROSY-HSQC spectra for TPP +-bound WT-EmrE and selected mutants. The S64V spectrum has sharper
peaks than the WT spectrum, suggesting that this mutation decreases the dynamics of EmrE. A59L and I101G both exhibit
significant line broadening, indicative of increased dynamics. Interestingly, peak doubling is still evident in the I101G
spectrum, indicating that this TM4 mutation alters EmrE's dynamics without disturbing dimerization. The spectrum of all
seven mutants can be found in Fig. S4.

throughout the spectrum. The 1 H– 15 N TROSY
spectrum of this mutant was similar to WT EmrE,
indicating that it has a very similar asymmetric dimer
structure. Indeed, chemical shift changes were greatest in the immediate vicinity of the mutation, as shown
on the three-dimensional structure in Fig. 6. Since the

90˚

chemical shifts reflect the unique environment of each
nucleus, these data indicated that the threedimensional structure of the asymmetric EmrE homodimer was very similar in WT EmrE and S64V-EmrE.
To determine whether S64V exhibited slower
dynamics, NMR exchange spectroscopy was used

Fig. 6. S64V mutation perturbs TM3 kink region
locally. Chemical shift differences between WT and
S64V-EmrE were plotted onto structure. The largest
perturbations are seen in the immediate vicinity of the
TM3 kink. Nevertheless, several smaller changes are
seen throughout the protein, suggesting several longrange allosteric effects of the S64V mutation.
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to directly determine the alternating access rate. For a
static structure, the ZZ-exchange spectrum will be
identical to the 1H– 15N TROSY spectrum. However, if
alternating access occurs during the delay period in
the ZZ-exchange experiment, additional cross-peaks
appear in the spectrum (Fig. 7a–c). By varying the

0.20

0.25

Fig. 7. S64V mutation slows down
conformational interconversion rate
of EmrE. (a) TROSY-HSQC (black)
overlay with a ZZ-exchange plane
with a mixing time of 200 ms (red) for
TPP +-bound S64V-EmrE. (b) Detail
showing the pair of G90 peaks and
their cross-peaks in the ZZ-exchange
spectrum. (c) Detail showing the pairs
of L83 and H110 peaks and their
cross-peaks in the ZZ-exchange
spectrum. (d) Composite peak ratio
fitting as a function of mixing time for
TPP +-bound S64V-EmrE in DMPC
(solid black) or DLPC (solid red)
bicelles. The dotted line indicates
the fit of TPP + -bound WT EmrE
(data in Fig. S5).

mixing time, the build-up of cross-peaks and decay of
autopeaks can be fit to quantitatively determine the
kinetics of alternating access (Fig. 7d), as we have
previously shown for WT EmrE [5]. The S64V
alternating access rate measured with these experiments is 0.6 ± 0.1 s −1, 8-fold slower than WT EmrE
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Table 2. S64V- and WT-EmrE drug binding affinity by ITC a
Substrate
S64V (DMPC/DHPC bicelles)
TPP+
EtTPP+
MeTPP+
WT (DMPC/DHPC bicelles)
TPP+
WT (DLPC/DHPC bicelles) [33]
TPP+
EtTPP+
MeTPP+
a

Kd (μM)

ΔH (kJ/mol)

n

0.6 ± 0.1
11.4 ± 0.1
60 ± 10

−52 ± 2
−51 ± 5
−40 ± 10

0.50 ± 0.03
0.51 ± 0.04
0.49 ± 0.01

0.5 ± 0.1

−29 ± 4

0.49 ± 0.03

0.45 ± 0.01
21.8 ± 0.7
130 ± 20

−22 ± 1
−16.6 ± 0.2
−12.7 ± 0.2

0.49 ± 0.05
0.57 ± 0.04
0.60 ± 0.04

Assays performed at 45 °C, pH 7.

under the same conditions (4.7 ± 0.6 s −1) [33]. In
addition, the individual peaks in the spectra are even
more intense and uniform in shape, suggesting less
structural plasticity in this mutant on all timescales.
Finally, we used isothermal titration calorimetry
(ITC) data to determine the affinity of S64V for several
different drug substrates. The data show that S64VEmrE binds TPP + , methyltriphenylphosphonium
(MeTPP +), and ethyltriphenylphosphonium (EtTPP +)
with affinities nearly identical to WT EmrE (Tables 2,
S1, and S2; and Fig. S6). This is consistent with
the NMR chemical shift data indicating very little
difference in the structure of this mutant and confirms
that impaired transport is not due to difference in
drug binding affinity. Thus, we have successfully
discovered a dynamics mutant that has a reduced rate
of alternating access without disrupting the structure
or substrate affinity of EmrE.

Discussion
In this study, we aimed to identify mutations that
suppressed the ability of EmrE to exchange between conformations open to either side of the
membrane. To this end, we performed the single
most extensive mutagenesis scan of EmrE to date,
testing the effect of mutations to one of three amino
acids (alanine, glycine, or valine) at each position on
resistance to three canonical EmrE substrates
(ethidium, acriflavine, or methyl viologen). From
this screen, we selected several mutants that
exhibited impaired drug resistance but normal drug
binding for further dynamics study. In a kinetic
assay, all of the mutants had reduced rates of proton
motive force-driven drug efflux in E. coli. Alternating
access in the drug-bound state is the rate-limiting
step in the transport cycle of TPP + by wild-type
EmrE [21,34]. Thus, we hypothesized that the
reduced rate of drug efflux by these mutants was
due to a decrease in the rate of this critical step.
Surprisingly, the rate of net drug efflux from E. coli
for our mutants does not correlate simply with the
rate of alternating access observed by NMR.

How might the rate of drug efflux be reduced despite
an increased rate of alternating access? EmrE's
transport mechanism is complex [21,35,36], so it is
possible that the mutations drastically reduced the
rates of steps other than alternating access, thereby
changing which step is rate limiting. However, in light
of the overall increased dynamics displayed by the
mutant spectra, it is important to note that decreased
transporter dynamics are not required for a decreased
rate of transport. Efficient drug efflux requires allosteric
communication between various regions of the protein, such that large-scale dynamic motions, including
the loop and helix rearrangements necessary for
alternating access, are properly coordinated to binding
of drug and proton. Loss of this coordination could
increase the rate of drug or proton leak pathways,
reducing the efficiency of transport even when
alternating access is fast [31].
Unfortunately, the lack of a high-resolution EmrE
structure precludes a deep understanding of its
allosteric couplings. Nevertheless, there are several
examples of known allosteric mechanisms that are
essential for proper transport. The first and most
important is the relationship between the alternating
access rate of EmrE and the occupancy of the E14
binding site. This rate varies over several orders of
magnitude depending on the identity of bound drug,
while in the absence of drug, it increases upon
protonation [22,33,37]. A second allosteric coupling
involves the TM2–3 loop, which exhibits increased
dynamics upon protonation of E14. This loop is
proposed to be involved in a latching mechanism,
wrapping around TM1 to stabilize the closure of the
transport pore on one side of the membrane and
prevent proton leak. Mutation of this loop to destabilize
the latch can abolish drug resistance (I54G, repeated
here in Table S1) and increase the alternating access
rate (I54L) [37]. A final set of couplings involve the
TM1–2 and TM3–4 loops. In an electron paramagnetic resonance study, it was shown that these loops
close to form an occluded state upon protonation of a
residue apart from E14 [36], which our NMR data
suggest is H110 [22,35]. Recently, we demonstrated
further coupling between the C-terminal tail, which
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includes H110, and the occupancy of the E14 binding
site. Consideration of these couplings led to our
proposal of an allosteric gating mechanism to prevent
futile proton transport in the absence of drug [35].
It seems likely that mutations that increase the
alternating access rate of EmrE disrupt one or more
of these mechanisms, resulting in the impaired drug
resistance phenotype. A59L is located at the
beginning of TM3, possibly disrupting stable closure
of the TM2–3 loop. Similarly, M21G is located at the
end of TM1 and could disturb EmrE gating by
disrupting the coupling of TM1, which contains the
critical E14 residue, with the rest of the transporter.
Previous comparison of the NMR chemical shifts of
TPP +-bound EmrE showed very little difference
between TM1 and TM2 in the two protomers of the
asymmetric homodimer [32], suggesting that the first
few helices move together as the protein switches
between open-in and open-out conformations. Loss
of this coordinated movement could disrupt the
transition and gating of EmrE.
It is more difficult to rationalize the effects of
I101G, N102A, and N102V within our current
understanding of EmrE structure and function. The
primary role of TM4 is thought to be dimerization
[10,38], holding the small EmrE homodimer together,
while it undergoes the large-scale conformational
changes needed to alternate access. However,
mutations at positions 101 and 102 did not disrupt
the EmrE dimer in previous mutagenesis studies and
do not disrupt dimerization in the mutants examined
here [13].
The answer could lie in the importance of the
65
GVG 67 motif, which forms a hinge point in TM3
[10]. In the available moderate-resolution structures,
this kink is only found in monomer A of the EmrE
homodimer [3,4,18]. The NMR chemical shift data
confirm this difference in TM3 structure between the
two halves of the dimer [5]. Thus, the TM3 helices
must alternately kink and straighten as EmrE
transitions between open-in and open-out conformations during each transport cycle. It is perhaps not
surprising then that the one slow dynamics mutant of
EmrE we identified, S64V, is adjacent to this motif.
Interestingly, residues 101 and 102 also pack
against this region. Re-examining our previous
studies of WT EmrE bound to diverse substrates
confirms the coupling between TM3 and this
segment of TM4: large chemical shift changes are
observed for TM4 residues at the level of the TM3
kink when EmrE is bound to different substrates
[33]. We previously attributed this to indirect effects
from structural changes in the TM3 kink that are
necessary for EmrE to accommodate diverse substrates. However, the dramatic phenotypes of
I101G, N102A, and N102V presented here suggest
that mutation of these residues may instead disrupt a
critical function of the TM3 kink. We are currently
exploring the effects of additional substitutions at

position 64 and the effect of the S64V mutation on
each step in the transport cycle. Ultimately, a deep
understanding of the importance of this region, and
of EmrE's broader transport mechanism, will require
a high-resolution structure. This effort is underway,
facilitated by the slow dynamics of the S64V mutant
presented here.

Materials and Methods
Screening for putative dynamics mutants
Every codon in the gene encoding EmrE was
mutated using degenerate oligonucleotides that converted a given codon to GBN, where B either is T, C, or
G and N is any base. Thus, every amino acid residue
was changed either to Val, Ala, or Gly [29]. The
mutagenic reactions (QuikChange II; Agilent) were
performed on the wild-type EmrE gene inserted under
the control of the tac promoter in plasmid pKK223–3
(making plasmid pKK56 [1]), transformed into E. coli
strain JM109 and colonies grown on 2xTY agar plates
containing 100 μg/ml ampicillin. Eight colonies were
picked from each mutagenic reaction, grown overnight at 37 °C in 1 ml 2xTY in a deep-well block, and
then this culture was diluted 1000-fold. The ability of
each EmrE mutant to transport substrates out of E. coli
was then assessed by spotting 5 μl of the diluted
culture onto 2xTY agar plates either containing methyl
viologen (50 or 200 μM), acriflavine (116 or 463 μM),
ethidium bromide (400 or 1500 μM), or control plates
containing no substrate. DNA sequencing was performed in parallel to determine which mutations were
present in each EmrE mutant. In the first round of
mutagenesis, 109 amino acid residues corresponding
to residues 2–110 of EmrE were mutated, and 276 of
the possible 327 mutants were obtained (Figs. S1 and
S2). The remaining 51 mutants were made using
oligonucleotides designed specifically to introduce a
single amino acid residue, sequenced and then tested
for their growth phenotype on the three substrates
(Fig. S3). Five mutants were not made (F44A, W63 V,
F79G, D84A, I88G). Growth was scored as robust at
both concentrations of a given substrate (++), growth
at both substrate concentrations but notably reduced
relative to WT at the higher concentration (+), growth
only at the lower substrate concentration (+/−), or no
growth at either substrate concentration (−) for each of
the three different substrates. Neither JM109 nor
JM109(pKK56) grew in the presence of any of the
substrate concentrations tested. Selected mutants
with impaired transport, as indicated by severe
defects in the growth assays, were then checked for
substrate binding using [ 3H]-TPP + binding assays
performed with the selected EmrE mutants purified in
DDM detergent using previously published methods
[39]. Data were gathered from a single experiment
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performed in triplicate. Reported errors are standard
error of mean.
ConSurf analysis
Sequence conservation analysis using ConSurf
[40–42] was performed on the EmrE amino acid
sequence using one iteration of HMMER to search
for homologs with E-value cutoff of 0.0001 against
protein database of UNIREF-90. A total of 300
sequences with that sample the list of homologs to
reference sequence were selected out of homology
search. These sequences were aligned using
MAFFT. Calculated Bayesian conservation scores
were mapped on the structure.
Sample preparation
WT and mutant EmrE was expressed, purified,
and reconstituted into DLPC or DMPC liposomes as
previously described [5,33]. Detergent was removed
by Amberlite® XAD®-2 resin, and 6:0 DHPC was
added to form isotropic bicelles as described in Ref.
[43]. Single point mutants were constructed using
QuikChange (Stratagene).
In-cell assay
These assays were carried out using BL21(DE3)
E. coli transformed with empty pET15b vector or
pET15b-EmrE with the specified WT or mutant
sequence. The cells were grown in M9 minimal
media with 100 μg/ml of ampicillin at 37 °C until the
OD600 reached 0.4. Then cells were induced with
0.33 mM IPTG at the same temperature for 30 min.
After induction, cell density was adjusted to OD600 =
0.4 followed by incubation with 2.5 μM ethidium
bromide and 40 μM carbonyl cyanide pchlorophenylhydrazone for an hour to load ethidium
bromide into the cells. The cell cultures were then
stored on ice until assays were complete. For each
experiment, 2 ml of cell culture was spun down and
immediately resuspended in 1 ml fresh M9 media with
2.5 μM ethidium bromide. Fluorescence of ethidium
bromide was monitored with an excitation wavelength
at 545 nm and emission wavelength at 610 nm. The
time course of fluorescence was plotted after normalization to the initial value of each run.
Western blot analysis of EmrE expression levels
Cells prepared for the in-cell transport assay as
described above were induced and adjusted to
OD600nm = 0.4. A 1-ml aliquot of this cell suspension was pelleted by centrifugation and resuspended in 40 μl of SDS-PAGE sample buffer. A 5-μl
sample was loaded on a 4%–12% Bis–Tris
NuPAGE gel (Thermo Fisher) and, following elec-
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trophoresis, transferred onto Immobilon PVDF
membrane (EMD-Millipore). The blot was probed
with anti-His6-HRP conjugated antibody (QIAGEN)
at 1:10,000 dilution, following the manufacturer's
instructions. Bands were visualized with ECL Prime
Western blotting kit (GE) according to the standard
protocol. HyBlot Films (Denville) were exposed for
3 min and captured with EZ doc imaging system
(BioRad).
NMR spectroscopy and data analysis
NMR data were collected using samples with 0.8–
1.5 mM 2H, 15N EmrE in DMPC/DHPC bicelles (q =
0.33, with a protein to DMPC molar ratio of 1:50) and
100 mM Mops, 10–30 mM NaCl, 2 mM TCEP, and
8%–10% D2O (pH 7) at 45 °C on a Varian 700-MHz
spectrometer with a room temperature probe unless
otherwise noted. All NMR spectra were processed with
NMRPipe [44] and analyzed in CcpNmr Analysis [45].
For the TPP +-bound EmrE, 2 mM TPP + was added to
ensure EmrE saturation. 2D 1H, 15N TROSY-HSQC
and TROSY-selected ZZ-exchange experiments [46]
with a lipid flip-back pulse [5] were carried out with a
recycle delay of 2 s and 128–144 increments.
Chemical shift differences (Δδ) between TPP +bound WT and S64V EmrE were calculated as a
weighted average of the differences in amide proton
(ΔδH) and nitrogen (ΔδN) chemical shifts according to:
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1Þ
Δδ ¼ Δδ H 2 þ ð0:154 Δδ N Þ2
The conformational interconversion rate, kconf, was
analyzed from the ZZ-exchange data as previously
described [47] using the composite peak ratio method
with an 11.1-ms offset time, t0, to account for the backtransfer time in the pulse sequence [22]. The
composite peak ratios of intensities of the autopeaks (IAA, IBB) and cross-peaks (IAB, IBA) were fit to
the following equation as a function of the delay time, t:
Ξðt Þ ¼

I AB ðt ÞI BA ðt Þ
≅k 2 ðt −t 0 Þ2 ð2Þ
I AA ðt ÞI BB ðt Þ−I AB ðt ÞI BA ðt Þ conf

For TPP +-bound EmrE, at least two planes were
collected with different mixing times and the mixing
times were adjusted according to the conformational
interconversion rate of each mutant. For S64V, the
slow rate of alternating access requires long mixing
times in order for measurable cross-peak build up and
the large size of bicelle-solubilized EmrE leads to
relatively fast relaxation, which limits the total possible
mixing time. Thus, for TPP +-bound S64V-EmrE,
mixing times of 100 and 200 ms were used in DLPC
bicelles and 200 and 225 ms in DMPC bicelles. For
TPP +-bound WT-EmrE in DMPC bicelles, conformational exchange is faster, and four planes with mixing
times of 20, 50, 90, and 125 ms were used to quantify
the rate of alternating access. The rate was determined

2787

Alternating-Access Dynamics Mutant of EmrE

by global fitting of all residues with resolved auto- and
cross-peaks in the spectra, and the standard deviation
of the rates determined by separately fitting individual
residues was used to estimate the error of the rates.
ITC
All ITC experiments were performed on a TA
instruments Nano-ITC calorimeter as previously described [33]. Data were fit to a model of ligand binding to
n independent and identical sites plus a constant
baseline due to mixing using the NanoAnalyze software
EmrE was reconstituted into DMPC/DHPC (q = 0.33)
isotropic bicelles in 20 mM potassium phosphate and
20 mM NaCl (pH 7) at 45 °C and loaded into the cell at
40–60 μM for TPP) titrations and 500 μM for titration
with MeTPP +, or EtTPP +. TPP + concentration in the
syringe was 150–200 μM. MeTPP + and EtTPP +
concentrations were 2–4 mM with buffer and bicelle
conditions that exactly matched the protein solution in
the cell. Titrations replicates are listed in Tables S1 and
S2. Reported errors are standard error of mean.
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